Top Page
Atomo Diagnostics Ltd.
(Sydney:AT1)
Atomo Diagnostics Ltd. (AT1) vs. iShares MSCI Australia ETF (EWA)
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Atomo Diagnostics Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.79M | 3.79M | 4.09M | 2.54M | 12.34M | 6.72M |
| Gross Profit | 1.79M | 1.79M | 1.44M | -6.08M | -1.85M | -1.71M |
| EBITDA | -4.69M | -4.69M | -6.12M | -9.00M | -4.72M | -4.70M |
| Net Income | -4.97M | -4.97M | -6.85M | -9.96M | -5.71M | -6.02M |
Balance Sheet | ||||||
| Total Assets | 9.28M | 9.28M | 11.38M | 16.47M | 26.62M | 32.24M |
| Cash, Cash Equivalents and Short-Term Investments | 3.22M | 3.22M | 3.69M | 6.47M | 12.97M | 17.95M |
| Total Debt | 185.10K | 185.10K | 84.67K | 254.88K | 340.81K | 67.59K |
| Total Liabilities | 2.30M | 2.30M | 1.29M | 1.68M | 1.81M | 2.15M |
| Stockholders Equity | 6.98M | 6.98M | 10.08M | 14.79M | 24.81M | 30.09M |
Cash Flow | ||||||
| Free Cash Flow | -1.99M | -1.99M | -4.70M | -6.25M | -5.11M | -10.12M |
| Operating Cash Flow | -1.96M | -1.96M | -4.69M | -5.85M | -2.81M | -4.23M |
| Investing Cash Flow | -33.89K | -33.89K | -16.08K | -401.28K | -2.31M | -5.90M |
| Financing Cash Flow | 1.46M | 1.46M | 1.87M | -170.75K | 17.61K | 997.37K |
Atomo Diagnostics Ltd. Technical Analysis
Atomo Diagnostics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | €36.47M | -6.73 | -513.22% | ― | -34.06% | 75.47% | |
45 Neutral | AU$13.43M | -1.63 | -103.74% | ― | 14.84% | 39.64% | |
43 Neutral | AU$21.87M | -3.51 | -58.27% | ― | -7.20% | 28.70% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
38 Underperform | AU$5.67M | -4.19 | ― | ― | ― | -55.00% | |
37 Underperform | AU$8.67M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics Ltd. announced the adoption of an amended constitution, as approved by its shareholders at the recent Annual General Meeting. This change reflects the company’s ongoing commitment to aligning its governance framework with its operational and strategic objectives, potentially impacting its market positioning and stakeholder engagement.
Atomo Diagnostics Limited announced the results of its 2025 Annual General Meeting, where all resolutions were passed by a poll. This announcement indicates a smooth decision-making process and reflects the company’s adherence to regulatory requirements, potentially strengthening stakeholder confidence.
Atomo Diagnostics Ltd. has released the MD & CEO’s address for their 2025 Annual General Meeting, highlighting the company’s ongoing commitment to innovation in the rapid diagnostic testing sector. This announcement underscores Atomo’s strategic focus on enhancing its market position by delivering cutting-edge diagnostic solutions, which is expected to positively impact its operations and stakeholder engagement.
Atomo Diagnostics Ltd. has made significant strides in the past year despite challenges in the global diagnostics sector. The company has advanced commercial partnerships, expanded international regulatory approvals, streamlined operations, and focused on high-value opportunities in infectious disease and rapid test applications. These efforts align with the growing trend towards decentralised, at-point-of-care, and self-testing solutions, reinforcing Atomo’s position in the market.
Atomo Diagnostics Ltd. has made significant commercial progress in Q1 FY26, highlighted by the submission of the FebriDx test for a CLIA waiver with the US FDA, following successful validation of the Pascal platform in clinical trials. The company has received substantial purchase orders from Lumos, totaling approximately $1 million, as part of their FebriDx agreement. Atomo’s HIV self-test has expanded its distribution channels, launching on Chemist Warehouse’s ecommerce site in Australia and receiving orders from USAID for Ukraine. Additionally, Atomo has secured $1.3 million in new capital to support ongoing business objectives, with a reported revenue of $680k for the quarter.
Atomo Diagnostics Limited announced it will release its Q1 FY26 results on October 29, 2025, followed by a webinar hosted by Managing Director & CEO, John Kelly. This announcement highlights Atomo’s ongoing commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations positively.
Atomo Diagnostics Ltd. has announced its Annual General Meeting (AGM) scheduled for October 31, 2025, at its headquarters in Leichhardt, NSW. The company is adapting to recent legislative changes by providing AGM materials electronically, encouraging shareholders to access documents online and submit proxies in advance, reflecting a shift towards more efficient and environmentally friendly communication practices.
Atomo Diagnostics Ltd. announced the issuance of 5,000,000 unquoted equity securities as part of an employee incentive scheme, with options expiring on June 30, 2028. This move is likely aimed at retaining and motivating employees, which could strengthen the company’s operational capabilities and competitive position in the healthcare diagnostics market.
Atomo Diagnostics Ltd. recently addressed a price query from the ASX, clarifying that they are unaware of any undisclosed price-sensitive information that could explain the recent trading activity in their securities. The company highlighted a recent purchase order for 65,000 HIV Self Test Kits for Ukraine, funded by USAID, but noted that the estimated revenue from this order does not meet their materiality threshold and thus was not announced on the ASX Market Announcements Platform. The company confirmed compliance with ASX disclosure rules and that their board authorized the responses.
Atomo Diagnostics Ltd has appointed Mr. Patrick Cook as the Independent Chair of the Board, succeeding Mr. John Kelly, who will now focus on his role as Managing Director. Mr. Cook brings over 35 years of experience in the medical devices and point-of-care diagnostics sectors, and his leadership is expected to guide Atomo through its strategic objectives as decentralized testing gains prominence in the diagnostic market.
Atomo Diagnostics Limited has released its FY25 financial results and will host a webinar for analysts and investors on September 2, 2025. The company continues to focus on expanding its presence in the global diagnostic market with its innovative rapid diagnostic test devices, which have been successfully commercialized internationally.
Atomo Diagnostics Ltd. has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, confirming compliance with key governance practices such as board charter disclosure, director appointment checks, and accountability of the company secretary to the board. This announcement underscores Atomo’s commitment to maintaining high standards of corporate governance, which is crucial for its operational integrity and stakeholder trust.
Atomo Diagnostics Limited reported a 7% decrease in revenue from ordinary activities, amounting to AUD 3,792,359 for the period ending June 30, 2025. Despite this, the company managed to reduce its loss from ordinary activities after tax by 27%, bringing it down to AUD 4,970,934. The basic and diluted earnings per share improved from the previous year, although no dividends were declared. The net tangible asset per ordinary security also decreased from 1.25 AUD cents in 2024 to 0.72 AUD cents in 2025, reflecting a challenging financial period. The financial statements have been audited with an unmodified opinion, and the company plans to hold its Annual General Meeting on or about October 31, 2025.
Atomo Diagnostics Ltd. announced that its Pascal test cassette has demonstrated exceptional performance in US clinical studies, supporting a CLIA waiver submission for Lumos’s FebriDx® test. The company has amended its agreement with Lumos to supply Pascal cassettes until 2031, with anticipated orders potentially reaching up to US$6.9 million over the first three years, contingent on the CLIA waiver and minimum order quantities. This development positions Atomo favorably in the US market, with Lumos expecting significant product sales from its agreement with PHASE Scientific.
Atomo Diagnostics Limited has requested a trading halt on its securities on the Australian Securities Exchange, pending an upcoming announcement about a significant supply contract. This move is aimed at managing the company’s continuous disclosure obligations and is expected to impact its operations by potentially enhancing its market position through the new contract.
Atomo Diagnostics Ltd. has announced the issuance of 22,519,555 unquoted equity securities in the form of options set to expire on August 14, 2028, with an exercise price of $0.04. This move is part of the company’s strategic financial management, potentially impacting its capital structure and providing opportunities for stakeholders to engage with the company’s growth trajectory.
Atomo Diagnostics Ltd. has announced the quotation of 22,519,555 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of August 14, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and stakeholder interests positively.
Atomo Diagnostics Limited has successfully completed a Shortfall Placement, raising $416,611.77 from institutional and sophisticated investors. This follows a recent order from Lumos Diagnostics for Atomo’s Pascal cassettes to support the increased demand for FebriDx® in the US market. The funds raised will support Atomo’s working capital and ongoing business objectives, positioning the company strongly for future operational activities.
Atomo Diagnostics Limited has secured a US$410,000 order from Lumos Diagnostics for Pascal cassettes, following Lumos’s agreement with PHASE Scientific to distribute the FebriDx test in the US. The FebriDx test, which uses Atomo’s Pascal cassette, has FDA clearance and is undergoing a CLIA waiver study. The agreement is expected to significantly boost demand for Atomo’s Pascal cassettes, with potential sales of up to US$316 million over six years, contingent on regulatory approvals and minimum order quantities.